Last reviewed · How we verify
NCT04096911
Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer
Status unknown
Phase 2
Last updated 20 September 2019
What this trial tests
Phase 2 trial testing Sintilimab in Uterine Cervical Neoplasms in 20 participants. Status unknown.
Timeline
31 July 2019
Primary endpoint
31 March 2021
31 March 2021
31 March 2021
Quick facts
| Lead sponsor | Buhai Wang |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 31 July 2019 |
| Primary completion | 31 March 2021 |
| Estimated completion | 31 March 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Sintilimab — full drug profile →
- quadrivalent HPV vaccine — full drug profile →
Conditions studied
- Uterine Cervical Neoplasms — all drugs for Uterine Cervical Neoplasms →
- Cervical Cancer — all drugs for Cervical Cancer →
- Cervical Neoplasms — all drugs for Cervical Neoplasms →
- Cervix Cancer — all drugs for Cervix Cancer →
Sponsor
Buhai Wang
Who can join
18 and older, female only, with Uterine Cervical Neoplasms or Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators propose to evaluate the efficacy of the combination of Pd-1 Monoclonal Antibody and HPV Vaccine in the patients with cervical cancer who fails in or can not endure the standard treatment
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence.
Wang Q, Peng H, Qi X, Wu M, et al · · 2020 · cited 114× · PMID 32728057 · DOI 10.1038/s41392-020-0199-6 -
Recent updates on Sintilimab in solid tumor immunotherapy.
Liu X, Yi Y. · · 2020 · cited 35× · PMID 33292551 · DOI 10.1186/s40364-020-00250-z -
Repurposing Infectious Diseases Vaccines Against Cancer.
Vandeborne L, Pantziarka P, Van Nuffel AMT, Bouche G. · · 2021 · cited 21× · PMID 34055652 · DOI 10.3389/fonc.2021.688755 -
The anti-PD-1 era of cervical cancer: achievement, opportunity, and challenge.
Li C, Cang W, Gu Y, Chen L, et al · · 2023 · cited 19× · PMID 37559727 · DOI 10.3389/fimmu.2023.1195476 -
HPV pathogenesis, various types of vaccines, safety concern, prophylactic and therapeutic applications to control cervical cancer, and future perspective.
Ashique S, Hussain A, Fatima N, Altamimi MA. · · 2023 · cited 14× · PMID 37363362 · DOI 10.1007/s13337-023-00824-z -
Sintilimab plus HPV vaccine for recurrent or metastatic cervical cancer.
Wang B, Liang Y, Wu Y, Li Q, et al · · 2024 · cited 6× · PMID 39608975 · DOI 10.1136/jitc-2024-009898 -
Drug repurposing as a potential source of innovative therapies in cervical cancer.
Capistrano I R, Paul S, Boere I, Pantziarka P, et al · · 2022 · cited 6× · PMID 36137575 · DOI 10.1136/ijgc-2022-003585 -
Immune checkpoint inhibitors in gynecologic oncology: Current status and perspectives.
Yanaihara N, Tse KY, Lee SJ, Yoo JG, et al · · 2025 · cited 4× · PMID 40908776 · DOI 10.1002/ijgo.70280
Verify or expand the search:
- PubMed search for NCT04096911
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sintilimab
Trials testing the same drug.
- NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
- NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
- NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
- NCT07468630 — Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma · Phase 2 · recruiting
- NCT07515625 — Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesop · Phase 2 · not yet recruiting
Other recruiting trials for Uterine Cervical Neoplasms
Currently open trials in the same condition.
- NCT07305727 — A Radiomic MRI Predictive Model for Response to Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer · recruiting
- NCT07011836 — Video-Based Patient Navigation to Support Cervical Cancer Screening Among Black Women · NA · recruiting
- NCT06815939 — Validation of a Lab-free Low-cost Screening Test for Prevention of Cervical Cancer · NA · recruiting
- NCT06558682 — Neoadjuvant Therapy in Cervical Cancer · NA · recruiting
- NCT06509724 — Comparison of Conventional and Hypofractionated IMRT in High-Risk Cervical Cancer Post-Radical Hysterectomy · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04096911 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Buhai Wang
- Last refreshed: 20 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04096911.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing